WallStreetZenWallStreetZen

NASDAQ: TCRT
Alaunos Therapeutics Inc Stock

$0.70+0.08 (+12.9%)
Updated Jun 21, 2024
TCRT Price
$0.70
Fair Value Price
$0.37
Market Cap
$11.21M
52 Week Low
$0.61
52 Week High
$7.80
P/E
-0.38x
P/B
2.34x
P/S
5,796.45x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.00k
Earnings
-$26.77M
Gross Margin
100%
Operating Margin
-514,120%
Profit Margin
-535,480%
Debt to Equity
0.26
Operating Cash Flow
-$23M
Beta
1.37
Next Earnings
Aug 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A

TCRT Overview

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TCRT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TCRT ($0.70) is overvalued by 87.47% relative to our estimate of its Fair Value price of $0.37 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TCRT ($0.70) is not significantly undervalued (87.47%) relative to our estimate of its Fair Value price of $0.37 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TCRT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TCRT due diligence checks available for Premium users.

Be the first to know about important TCRT news, forecast changes, insider trades & much more!

TCRT News

Valuation

TCRT fair value

Fair Value of TCRT stock based on Discounted Cash Flow (DCF)
Price
$0.70
Fair Value
$0.37
Overvalued by
87.47%
TCRT ($0.70) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TCRT ($0.70) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TCRT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TCRT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.38x
Industry
-5.75x
Market
30.75x

TCRT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.34x
Industry
6.2x
TCRT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TCRT's financial health

Profit margin

Revenue
$0.0
Net Income
-$1.7M
Profit Margin
0%
TCRT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TCRT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$6.0M
Liabilities
$1.2M
Debt to equity
0.26
TCRT's short-term assets ($6.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TCRT's short-term assets ($6.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TCRT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TCRT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.9M
Investing
$0.0
Financing
$0.0
TCRT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TCRT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
TCRT$11.21M+12.54%-0.38x2.34x
CANF$11.12M+0.55%-0.91x1.78x
DOMH$11.39M-2.56%-0.41x0.24x
ELAB$10.96M-1.53%-1.57x4.41x
COEP$11.51M+4.73%-0.57x2.64x

Alaunos Therapeutics Stock FAQ

What is Alaunos Therapeutics's quote symbol?

(NASDAQ: TCRT) Alaunos Therapeutics trades on the NASDAQ under the ticker symbol TCRT. Alaunos Therapeutics stock quotes can also be displayed as NASDAQ: TCRT.

If you're new to stock investing, here's how to buy Alaunos Therapeutics stock.

What is the 52 week high and low for Alaunos Therapeutics (NASDAQ: TCRT)?

(NASDAQ: TCRT) Alaunos Therapeutics's 52-week high was $7.80, and its 52-week low was $0.61. It is currently -91.03% from its 52-week high and 14.75% from its 52-week low.

How much is Alaunos Therapeutics stock worth today?

(NASDAQ: TCRT) Alaunos Therapeutics currently has 16,012,522 outstanding shares. With Alaunos Therapeutics stock trading at $0.70 per share, the total value of Alaunos Therapeutics stock (market capitalization) is $11.21M.

Alaunos Therapeutics stock was originally listed at a price of $240.00 in Aug 24, 2005. If you had invested in Alaunos Therapeutics stock at $240.00, your return over the last 18 years would have been -99.71%, for an annualized return of -27.7% (not including any dividends or dividend reinvestments).

How much is Alaunos Therapeutics's stock price per share?

(NASDAQ: TCRT) Alaunos Therapeutics stock price per share is $0.70 today (as of Jun 21, 2024).

What is Alaunos Therapeutics's Market Cap?

(NASDAQ: TCRT) Alaunos Therapeutics's market cap is $11.21M, as of Jun 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Alaunos Therapeutics's market cap is calculated by multiplying TCRT's current stock price of $0.70 by TCRT's total outstanding shares of 16,012,522.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.